{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:37:41Z","timestamp":1793828261308,"version":"4.6.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Research and Development Program of the Autonomous Region","award":["(2024B03032-1)"],"award-info":[{"award-number":["(2024B03032-1)"]}]},{"name":"Tianshan Talent Training Program of Xinjiang Uygur Autonomous Region","award":["(2022TSYCLJ0001)"],"award-info":[{"award-number":["(2022TSYCLJ0001)"]}]},{"name":"National Natural Science Foundation of China- Regional Project","award":["(82460068)"],"award-info":[{"award-number":["(82460068)"]}]},{"name":"The Key Project of Xinjiang Natural Science Foundation","award":["(2024D01D22)"],"award-info":[{"award-number":["(2024D01D22)"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(82460097)"],"award-info":[{"award-number":["(82460097)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Science and Technology Support Project of Xinjiang","award":["(2024E02043)"],"award-info":[{"award-number":["(2024E02043)"]}]},{"name":"Innovation Team Training Program of First Affiliated Hospital of Xinjiang Medical University"},{"name":"Tianshan Talents training program","award":["(2022TSYCLJ0030)"],"award-info":[{"award-number":["(2022TSYCLJ0030)"]}]},{"name":"Key research and development project of Xinjiang Uygur Autonomous Region","award":["(2022B03022-4)"],"award-info":[{"award-number":["(2022B03022-4)"]}]},{"name":"Urumqi Science and Technology Program Project","award":["(P161310003)"],"award-info":[{"award-number":["(P161310003)"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>\n                    The bempedoic acid plus ezetimibe fixed-dose combination (BAPEFC) is a novel lipid-lowering agent that was successively marketed in regions such as the United States and the European Union in 2020. It significantly reduces low-density lipoprotein cholesterol through a dual mechanism of inhibiting adenosine triphosphate-citrate lyase and Niemann-Pick C1-like 1. Although clinical trials have confirmed its efficacy, its long-term safety in the real world requires further evaluation. All adverse event reports related to BAPEFC from the first quarter of 2020 to the first quarter of 2025 were extracted from the FDA Adverse Event Reporting System (FAERS) database. After data standardization, a comprehensive evaluation of adverse reaction signals was performed using the reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker methods. Subgroup analyses by sex and age were further conducted for newly identified adverse drug reactions. A total of 875 reports involving at least 1 BAPEFC agent were identified in FAERS. The preferred term with the highest number of reports was arthralgia (n\u2005=\u2005103), while the strongest positive signal was for tendon discomfort (n\u2005=\u20053, ROR\u2005=\u2005135.27, proportional reporting ratio\u2005=\u2005135.03, information component\u2005=\u20057.06, empirical Bayes geometric mean\u2005=\u2005133.36). At the system organ class level, musculoskeletal and connective tissue disorders had the highest ROR value (ROR\u2005=\u20056.02, 95% confidence interval [CI]: 5.46\u20136.63). The newly identified signal for \u201cBlood Triglycerides Increased\u201d showed statistically significant ROR signals in both male and female subgroups (ROR\u2005=\u200536.59 [95% CI: 15.16\u201388.32] vs ROR\u2005=\u200534.78 [95% CI: 15.57\u201377.67]), and the adjusted Bonferroni-\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    values were statistically significant (Bonferroni-\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001). Subgroup analysis of the combined data for the newly identified \u201cPancreatitis\u201d and \u201cPancreatitis Acute\u201d showed statistically significant ROR signals in both the non-elderly subgroup (&lt;65 years) and the elderly subgroup (\u226565 years) (ROR\u2005=\u200510.43 [95% CI: 4.32\u201325.18] vs ROR\u2005=\u20055.88 [95% CI: 2.2\u201315.71]), and the adjusted Bonferroni-\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    values were statistically significant (Bonferroni-\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0003 vs Bonferroni-\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0106). Based on the FAERS database, this study provides the first comprehensive and systematic analysis of adverse drug events associated with BAPEFC. It newly identifies several adverse drug reactions not mentioned in the prescribing information, such as blood triglycerides increased, pancreatitis, and pancreatitis acute, thereby offering evidence for clinical monitoring and identification of potential risks associated with BAPEFC.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047898","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:01:23Z","timestamp":1772240483000},"page":"e47898","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A real-world pharmacovigilance study of bempedoic acid plus ezetimibe fixed-dose combination based on the FDA FAERS database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3514-0668","authenticated-orcid":false,"given":"Bing","family":"Zhu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Shao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cui","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019.","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"R3-20260413","first-page":"84","article-title":"Bempedoic acid: a novel oral LDL-cholesterol lowering agent.","volume":"14","author":"Jialal","year":"2022","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events.","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R5-20260413","first-page":"1","article-title":"Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database.","volume":"19","author":"Wang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R6-20260413","first-page":"1","article-title":"Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS database.","volume":"26","author":"Han","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"1480994","DOI":"10.3389\/fphar.2024.1480994","article-title":"Drug-induced hearing disorders: a disproportionality analysis of the FAERS database.","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prevent Cardiol"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP).","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"e70167","DOI":"10.1111\/eci.70167","article-title":"Atherogenic dyslipidaemia and residual cardiovascular risk: understanding the link to heart disease.","volume":"56","author":"Gir\u00f3n","year":"2026","journal-title":"Eur J Clin Invest"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clinthera.2020.12.001","article-title":"Bempedoic acid: a new tool in the battle against hyperlipidemia.","volume":"43","author":"Powell","year":"2021","journal-title":"Clin Ther"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jacl.2024.12.014","article-title":"Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR outcomes trial.","volume":"19","author":"Laufs","year":"2025","journal-title":"J Clin Lipidol"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/biomedicines13061460","article-title":"Reshaping dyslipidaemia treatment with bempedoic acid\u2014a narrative review.","volume":"13","author":"Strikic","year":"2025","journal-title":"Biomedicines"},{"key":"R17-20260413","first-page":"40","article-title":"Efficacy and safety of bempedoic acid in patients with hyperlipidemia and non-alcoholic fatty liver disease.","volume":"14","author":"Nisar","year":"2024","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40261-021-01075-w","article-title":"Bempedoic acid: a new non-statin drug for the treatment of dyslipidemia.","volume":"41","author":"Wichaiyo","year":"2021","journal-title":"Clin Drug Investig"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials.","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies.","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice.","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.33.498","article-title":"Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human.","volume":"33","author":"Sato","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.","volume":"16","author":"Laufs","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"132305","DOI":"10.1016\/j.ijcard.2024.132305","article-title":"Safety evaluation of bempedoic acid: a pharmacovigilance analysis using FDA adverse event reporting system data.","volume":"412","author":"Li","year":"2024","journal-title":"Int J Cardiol"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40256-022-00552-7","article-title":"Potential cardiovascular events avoided with bempedoic acid plus ezetimibe fixed-dose combination compared with ezetimibe alone in patients with atherosclerotic cardiovascular disease taking maximally tolerated statins.","volume":"23","author":"McQueen","year":"2022","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:17:31Z","timestamp":1785784651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047898","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}